BioSpace News Archive

LENZ Therapeutics announced today that it has raised $83.5 million in an oversubscribed Series B financing.

9 Meters Biopharma, Inc. today announced that John Temperato, President and Chief Executive Officer of 9 Meters, is scheduled to present at the Oppenheimer 33rd Annual Healthcare Conference.

Today, Biotricity highlighted several of its major operating achievements since fiscal year 2022.

Arcturus Therapeutics Holdings Inc. today announced that it will release its financial results for the quarter and year ended December 31, 2022 after the market close on Tuesday, March 28 and will also host a conference call and webcast at 4:30 p.m. Eastern Time on March 28, 2023.

Shorla Oncology (‘Shorla’), a US-Ireland pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved the company’s oncology drug, Nelarabine Injection, for the treatment of T-cell Acute Lymphoblastic Leukemia (T-ALL) and T-cell Lymphoblastic Lymphoma (T-LBL).

Cerevance, a private, clinical-stage drug discovery and development company focused on developing novel therapeutics for central nervous system (CNS) diseases using the company’s proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) platform, today announced plans to present at the Alzheimer’s Research UK Conference 2023, held in Aberdeen, Scotland and virtually from March 14-15, 2023.

Processa Pharmaceuticals, Inc. today announced that the Company’s President & CEO, Dr. David Young, will present virtually at the Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023 at 12:00 PM Eastern.

Argon Medical Devices, a leading provider of device solutions for Interventional Radiology, Vascular Surgery, Interventional Cardiology, and Oncology, introduces the TRAVELER™ Portal Vein Access Series as the newest addition to its portal vein access product portfolio.

Elevar Therapeutics, Inc. announced the opening of its new corporate headquarters in Fort Lee, New Jersey.

Paragonix Technologies, Inc., a leading organ transplant company, announced that it has secured $24 million in Series B funding, led by Signet Healthcare Partners.